Dazucorilant
Small moleculeexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 27, 2020 (NCT04249323)
Timeline
Indications
Mechanism of action
- Glucocorticoid receptorMODULATOR
NR3C1 modulator
Chemistry & pharmacology
Loading structure…
SMILES
O=C(c1ccccn1)[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCN(S(=O)(=O)c1ccc(C(F)(F)F)cc1)C2- Mol. weight
- 582.58 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3734774 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06928779 | Phase 1 | Oct 8, 2024 | Corcept Therapeutics |
| NCT06495944 | Phase 1 | May 31, 2024 | Corcept Therapeutics |
| NCT05407324 | Phase 2 | Sep 30, 2022 | Corcept Therapeutics |
| NCT04990310 | Phase 1 | Aug 18, 2021 | Corcept Therapeutics |
| NCT04994743 | Phase 1 | Jul 13, 2021 | Corcept Therapeutics |
| NCT04249323 | Phase 1 | Jan 27, 2020 | Corcept Therapeutics, Quotient |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Corcept Therapeutics | For profit | 6 | 6 | 2 | 2020 |
| Quotient | For profit | 1 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1